ClinicaliQ Trial Snapshot
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Active Not Recruiting • Phase III • Rheumatology • NCT06143878.
- Trial testing JNJ-77242113 against placebo and deucravacitinib for moderate to severe plaque psoriasis effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib. Conditions: Plaque Psoriasis Interventions: JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 774 participants